Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1998-3-26
|
| pubmed:abstractText |
Cadherins are a family of glycoproteins that are associated with cell adhesion mechanisms. They are divided into subclasses. The E- and P-cadherins are regarded as the epithelial subtype. Their expression has been demonstrated in many different carcinoma types. Using immunomorphological techniques, we studied the expression of E-cadherin in a series of 145 human brain tumours with the monoclonal antibody 5H9. Western blot analysis was used to confirm the immunohistochemical data. The tumour types represented were astrocytoma WHO I (n = 7), astrocytoma WHO II (n = 6), astrocytoma WHO III (n = 14), glioblastoma WHO IV (n = 8), oligodendroglioma WHO II (n = 5), ependymoma WHO II (n = 5), choroid plexus papilloma WHO I (n = 5), pineoblastoma WHO IV (n = 5), medulloblastoma WHO IV (n = 5), neurinoma WHO I (n = 5), meningioma WHO I and WHO III (n = 75) and pituitary adenoma WHO I (n = 5). Only choroid plexus papillomas (5/5) and meningiomas showed E-cadherin expression. In benign meningiomas (n = 45; 100%), positive E-cadherin immunoreactivity was found regardless of the histomorphological subtype. E-Cadherin was also expressed in 21 WHO I meningiomas (100%) invading dura, bone, brain, and muscle. In contrast, E-cadherin was absent from the majority of morphologically malignant meningiomas (6/9, 66.6%). In addition, in recurrent meningiomas (n = 9), E-cadherin expression in the recurrent tumours was identical to that in the primary neoplasm except in cases with malignant progression, where the malignant recurrent tumour was E-cadherin negative. In 2 cases of metastasizing meningiomas, no E-cadherin immunoreactivity was found in the primary tumours or their metastases.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0945-6317
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
432
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
163-7
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9504862-Adult,
pubmed-meshheading:9504862-Aged,
pubmed-meshheading:9504862-Antibodies, Monoclonal,
pubmed-meshheading:9504862-Blotting, Western,
pubmed-meshheading:9504862-Cadherins,
pubmed-meshheading:9504862-Female,
pubmed-meshheading:9504862-Glioma,
pubmed-meshheading:9504862-Humans,
pubmed-meshheading:9504862-Immunochemistry,
pubmed-meshheading:9504862-Immunohistochemistry,
pubmed-meshheading:9504862-Male,
pubmed-meshheading:9504862-Meningeal Neoplasms,
pubmed-meshheading:9504862-Meningioma,
pubmed-meshheading:9504862-Middle Aged,
pubmed-meshheading:9504862-Neoplasm Recurrence, Local,
pubmed-meshheading:9504862-Retrospective Studies
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
E-Cadherin in human brain tumours: loss of immunoreactivity in malignant meningiomas.
|
| pubmed:affiliation |
Institut für Neuropathologie, Universität-Gesamthochschule, Essen, Germany.
|
| pubmed:publicationType |
Journal Article
|